Vitamin D3 from Ultraviolet-B Exposure or Oral Intake in Relation to Cancer Incidence and Mortality.

Abstract

PURPOSE OF REVIEW:

This review summarizes the understanding of vitamin D3's role in reducing risk of cancer incidence and mortality.

RECENT FINDINGS:

Recent randomized clinical trials and observational studies of participants who took part in vitamin D3 supplementation studies provide increasing evidence that concentrations of serum 25-hydroxyvitamin D3 [25(OH)D3] up to ~ 60 ng/ml are inversely correlated with all cancer and some specific cancers' incidence and death, with a stronger effect on survival and death than on incidence. Mechanisms linking vitamin D3 to effects on cellular proliferation, anti-angiogenesis, and anti-metastasis continue to be found. Vitamin D3 reduces cancer risk causally. Maintaining 25(OH)D3 in the range of 40-60 ng/ml reduces the risk of many cancers. Raising 25(OH)D3 concentrations after diagnosis to that range increases survival rates and could significantly reduce the global burden of cancer incidence and death.

• Authors: William B Grant, Meis Moukayed
• Journal: Current nutrition reports (Curr Nutr Rep) Vol. 8 Issue 3 Pg. 203-211 (09 2019) ISSN: 2161-3311 [Electronic] United States
• PMID: 31055734 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Cholecalciferol
• Calcifediol

Topics

• Angiogenesis Inhibitors (pharmacology)
• Apoptosis (drug effects)
• Calcifediol (blood)
• Cell Adhesion
• Cell Proliferation (drug effects)
• Cholecalciferol (blood, pharmacology)
• Dietary Supplements
• Humans
• Incidence
• Neoplasm Metastasis (prevention & control)
• Neoplasms (epidemiology, prevention & control)
• Oxidative Stress
• Tumor Microenvironment
• Ultraviolet Rays